Ireland· IE-PA-EU/1/22/1630/001
KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion
A antineoplastic agents product containing tebentafusp, registered in Ireland by Immunocore Ireland Limited. The same ATC class is registered in 6 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Tebentafusp is registered in 6 of 19 countries.
Countries holding a registration under ATC L01 (antineoplastic agents), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 3 of them publish a price we can compare per daily dose
Tebentafusp · ATC L01
6 / 19 countries
- Canada
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
The record
At a glance
HPRA (Ireland)- Active substance
- Tebentafusp
- Manufacturer
- Immunocore Ireland Limited
- Country
- Ireland (IE)
- ATC code
- L01
- ATC class
- ANTINEOPLASTIC AGENTS
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/22/1630/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tebentafusp in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesKIMMTRAKImmunocore Commercial LLC
- CzechiaKIMMTRAKImmunocore Ireland Limited, Dublin
- FinlandKIMMTRAKImmunocore Ireland Limited
- BelgiumKimmtrak 100 µg/0.5 mlImmunocore Ireland
- PolandKIMMTRAKImmunocore Ireland Ltd.
- SwedenKIMMTRAK 100 mikrogram/ 0,5 ml Koncentrat till infusionsvätska, lösningImmunocore Ireland Limited
- NorwayKimmtrakImmunocore Ireland Limited
- CanadaKIMMTRAKIMMUNOCORE IRELAND LIMITED
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kimmtrak
- Liechtenstein · Kimmtrak
- Norway · Kimmtrak
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0ddfd25a-0827-4d4b-8a0c-0df997e9f14b GET /v1/drugs/0ddfd25a-0827-4d4b-8a0c-0df997e9f14b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L01"
],
"strength": null,
"pa_number": "EU/1/22/1630/001",
"substances": [
"Tebentafusp"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "01/04/2022",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about tebentafusp.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.